These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29146922)

  • 21. Structure and mechanism of a transmission blocking vaccine candidate protein Pfs25 from P. falciparum: a molecular modeling and docking study.
    Sharma B
    In Silico Biol; 2008; 8(3-4):193-206. PubMed ID: 19032156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional evaluation of malaria Pfs25 DNA vaccine by in vivo electroporation in olive baboons.
    Kumar R; Nyakundi R; Kariuki T; Ozwara H; Nyamongo O; Mlambo G; Ellefsen B; Hannaman D; Kumar N
    Vaccine; 2013 Jun; 31(31):3140-7. PubMed ID: 23684840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of Recombinant
    Parzych EM; Miura K; Ramanathan A; Long CA; Burns JM
    Infect Immun; 2018 Jan; 86(1):. PubMed ID: 28993460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A region of Plasmodium falciparum antigen Pfs25 that is the target of highly potent transmission-blocking antibodies.
    Stowers AW; Keister DB; Muratova O; Kaslow DC
    Infect Immun; 2000 Oct; 68(10):5530-8. PubMed ID: 10992450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity.
    Farrance CE; Chichester JA; Musiychuk K; Shamloul M; Rhee A; Manceva SD; Jones RM; Mamedov T; Sharma S; Mett V; Streatfield SJ; Roeffen W; van de Vegte-Bolmer M; Sauerwein RW; Wu Y; Muratova O; Miller L; Duffy P; Sinden R; Yusibov V
    Hum Vaccin; 2011; 7 Suppl():191-8. PubMed ID: 21266847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults.
    Chichester JA; Green BJ; Jones RM; Shoji Y; Miura K; Long CA; Lee CK; Ockenhouse CF; Morin MJ; Streatfield SJ; Yusibov V
    Vaccine; 2018 Sep; 36(39):5865-5871. PubMed ID: 30126674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay.
    Miura K; Takashima E; Deng B; Tullo G; Diouf A; Moretz SE; Nikolaeva D; Diakite M; Fairhurst RM; Fay MP; Long CA; Tsuboi T
    Infect Immun; 2013 Dec; 81(12):4377-82. PubMed ID: 24042109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial.
    de Graaf H; Payne RO; Taylor I; Miura K; Long CA; Elias SC; Zaric M; Minassian AM; Silk SE; Li L; Poulton ID; Baker M; Draper SJ; Gbesemete D; Brendish NJ; Martins F; Marini A; Mekhaiel D; Edwards NJ; Roberts R; Vekemans J; Moyle S; Faust SN; Berrie E; Lawrie AM; Hill F; Hill AVS; Biswas S
    Front Immunol; 2021; 12():694759. PubMed ID: 34335606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates.
    Lee SM; Wu CK; Plieskatt J; McAdams DH; Miura K; Ockenhouse C; King CR
    Malar J; 2016 Aug; 15(1):405. PubMed ID: 27515826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural vaccinology of malaria transmission-blocking vaccines.
    Patel PN; Tolia N
    Expert Rev Vaccines; 2021 Feb; 20(2):199-214. PubMed ID: 33430656
    [No Abstract]   [Full Text] [Related]  

  • 31. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals.
    Barr PJ; Green KM; Gibson HL; Bathurst IC; Quakyi IA; Kaslow DC
    J Exp Med; 1991 Nov; 174(5):1203-8. PubMed ID: 1940798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies.
    Lobo CA; Dhar R; Kumar N
    Infect Immun; 1999 Apr; 67(4):1688-93. PubMed ID: 10085005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Global diversity of the gene encoding the Pfs25 protein-a Plasmodium falciparum transmission-blocking vaccine candidate.
    Sookpongthai P; Utayopas K; Sitthiyotha T; Pengsakul T; Kaewthamasorn M; Wangkanont K; Harnyuttanakorn P; Chunsrivirot S; Pattaradilokrat S
    Parasit Vectors; 2021 Nov; 14(1):571. PubMed ID: 34749796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25.
    Kubler-Kielb J; Majadly F; Wu Y; Narum DL; Guo C; Miller LH; Shiloach J; Robbins JB; Schneerson R
    Proc Natl Acad Sci U S A; 2007 Jan; 104(1):293-8. PubMed ID: 17190797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle.
    Shimp RL; Rowe C; Reiter K; Chen B; Nguyen V; Aebig J; Rausch KM; Kumar K; Wu Y; Jin AJ; Jones DS; Narum DL
    Vaccine; 2013 Jun; 31(28):2954-62. PubMed ID: 23623858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice.
    Jones RM; Chichester JA; Mett V; Jaje J; Tottey S; Manceva S; Casta LJ; Gibbs SK; Musiychuk K; Shamloul M; Norikane J; Mett V; Streatfield SJ; van de Vegte-Bolmer M; Roeffen W; Sauerwein RW; Yusibov V
    PLoS One; 2013; 8(11):e79538. PubMed ID: 24260245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
    An SJ; Scaria PV; Chen B; Barnafo E; Muratova O; Anderson C; Lambert L; Chae MH; Yang JS; Duffy PE
    Vaccine; 2018 May; 36(21):2978-2984. PubMed ID: 29681410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.
    Wu Y; Ellis RD; Shaffer D; Fontes E; Malkin EM; Mahanty S; Fay MP; Narum D; Rausch K; Miles AP; Aebig J; Orcutt A; Muratova O; Song G; Lambert L; Zhu D; Miura K; Long C; Saul A; Miller LH; Durbin AP
    PLoS One; 2008 Jul; 3(7):e2636. PubMed ID: 18612426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-Pfs25 human plasma reduces transmission of Plasmodium falciparum isolates that have diverse genetic backgrounds.
    Da DF; Dixit S; Sattabonkot J; Mu J; Abate L; Ramineni B; Ouedraogo JB; MacDonald NJ; Fay MP; Su XZ; Cohuet A; Wu Y
    Infect Immun; 2013 Jun; 81(6):1984-9. PubMed ID: 23509152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation.
    LeBlanc R; Vasquez Y; Hannaman D; Kumar N
    Vaccine; 2008 Jan; 26(2):185-92. PubMed ID: 18054817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.